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Invasive meningococcal disease caused by Neisseria meningitidis is a life-threatening disease. Several coun-
tries now include meningococcal serogroup C (MenC) conjugate and, more recently, a meningococcal ser-
ogroup ACWY conjugate (MenACWY) vaccination in their national immunization schedules. DTaP-IPV-
HB-PRP-T is a hexavalentvaccine thatprovidesprotection against sixdiseases. Thephase III, open-label, ran-
domised,multicentre study enrolled healthy toddlers who received the DTaP-IPV-HB-PRP-T vaccine (at 2, 3
and4 months)withorwithout aMenCvaccine (at2 and4 months) in theprimary series study. At12 months
of age, 312 toddlers were randomised to receive DTaP-IPV-HB-PRP-T co-administered with MenACWY-TT
vaccine (Group A; n = 104); DTaP-IPV-HB-PRP-T vaccine alone (Group B; n = 105); orMenACWY-TT vaccine
alone (Group C; n = 103). At 12 months of age, there were no notable differences in terms of antibody per-
sistence for any DTaP-IPV-HB-PRP-T vaccine antigen, whether MenC-TT conjugate vaccine was co-
administered or not during the primary series. Following booster vaccination, immune responses to
DTaP-IPV-HB-PRP-T and MenACWY-TT vaccines were not affected by co-administration. One month after
vaccination, the immune responses elicited by both vaccines were high, whether administered concomi-
tantly or separately. The administration of MenC vaccine during infancy did not preclude the use of a
MenACWY-TT vaccine for booster vaccination. Even though the reactogenicity after co-administration
was somewhat higher, the results of this study support the concomitant administration of the DTaP-IPV-
HB-PRP-T vaccine with a MenACWY-TT conjugate vaccine when given from 12 months of age.
The clinical trial registration numbers are: clinicaltrial.gov: NCT01839175; EudraCT: 2012-005547-24.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction serogroup distribution [3,4]. Fatality rates for cases of invasiveInvasive meningococcal disease is a contagious and life-
threatening infection caused by Neisseria meningitidis, a Gram-
negative endotoxin-producing bacterium known for its ability
to cause epidemic disease [1,2]. Meningococcal disease occurs
worldwide, with considerable geographical variability inmeningococcal disease are between 5% and 15%, with 20% of sur-
vivors suffering permanent sequelae including hearing loss, neu-
rological impairment, seizures and intellectual disabilities [5].
Several countries including the UK formerly introduced
meningococcal serogroup C conjugate (MenC)3 vaccination and,
more recently, a meningococcal serogroup ACWY conjugatehomas),
orms; D,
e b; IPV,
; Men C,
capsular
s toxoid.
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ules [6].
The hexavalent diphtheria (D), tetanus (T), acellular pertussis
(aP), inactivated poliovirus (IPV), hepatitis B (HB), Haemophilus
influenzae type-b (Hib) capsular polyribosyl-ribitol-phosphate
(PRP) vaccine (DTaP-IPV-HB-PRP-T; Hexyon, Hexacima, Hex-
axim, Sanofi Pasteur; Lyon, France) is a fully liquid ready-to-use
combination vaccine that provides protection against six diseases.
A primary series vaccination study designed to assess the immuno-
genicity and safety of DTaP-IPV-HB-PRP-T when administered con-
comitantly with a MenC vaccine during the first year of life, and
whether concomitant administration has any impact on the
immunogenicity and safety of either vaccine has already been pub-
lished [7]. The data presented here report the immunogenicity
results and safety findings from the booster part of the previous
two–three-four month primary series study that assessed the co–
administration of a booster dose of the DTaP-IPV-HB-PRP-T vaccine
with a MenACWY-tetanus toxoid (TT) vaccine. In this study a boos-
ter dose of a MenACWY vaccine following a childhood MenC vacci-
nation was tested as vaccination with MenACWY is already (or
likely to be in the near future) the preferred recommended immu-
nisation schedule against meningococcal diseases.1.1. Objectives
The primary objective of this booster part of the primary study
was to describe the immunogenicity of a booster dose of the DTaP-
IPV-HB-PRP-T vaccine and a MenACWY-TT vaccine either co-
administered at 12 months of age or given separately.
The secondary objective was to describe the antibody persis-
tence at 12 months of age for the DTaP-IPV-HB-PRP-T vaccine fol-
lowing a three–dose primary vaccination at two, three and four
months of age (prior to administration of a booster dose). The sec-
ondary objectives included the description of the safety of a boos-
ter dose of the DTaP-IPV-HB-PRP-T vaccine and MenACWY-TT
vaccine either co–administered at 12 months of age or given sepa-
rately. The study was descriptive; no formal hypotheses were
tested.2. Materials and methods
2.1. Study population
Healthy toddlers who received three doses of the DTaP-IPV-HB-
PRP-T vaccine in the primary series study were eligible for
enrolment.
The main exclusion criteria were:
 previous booster vaccination against diphtheria, tetanus, per-
tussis, hepatitis B, poliomyelitis, Hib, or meningococcus with
either the DTaP-IPV-HB-PRP-T vaccine or another vaccine
 previous (within four weeks) or planned vaccination during
study participation,
 any history of diphtheria, tetanus, pertussis, poliomyelitis, hep-
atitis B, Hib or meningococcal serogroup A, C, W or Y infection
(s) confirmed either clinically, serologically or microbiologically
 known or suspected contraindication(s) to any of the study
vaccines
 hypersensitivity or allergy to components of the study vaccines
 receipt of anticoagulants in the previous three weeks, con-
traindicating intramuscular injection
 receipt of high doses of systemic corticosteroid therapy or other
immunosuppressive therapy in the previous three months
 any recent history of chronic disease or medical condition likely
to interfere with the trial assessments.2.2. Vaccines and vaccinations
All vaccines were administered according to their respective
summaries of product characteristics [8–12]. The hexavalent
DTaP-IPV-HB-PRP-T vaccine (0.5 mL; batch number: S4370) and/
or MenACWY-TT vaccine (0.5 mL; Nimenrix manufactured by
GlaxoSmithKline Biologicals SA; batch number: A90CA032A) were
administered intramuscularly in the anterolateral aspect of the
right thigh. NeisVac-C (Baxter AG; batch number: VNS1M04C)
and Prevenar 13 (Pfizer; batch number: G40914) with or without
measles, mumps and rubella vaccine (live) (M-M-RvaxPro; Merck
Sharp & Dohme Corporation; batch number: J011869) were admin-
istered 5 cm apart in the left thigh.
Further details of the vaccines used are provided in Supplemen-
tary Data 1. The administration of MenACWY-TT was performed
either at least one month before (Group C; control group for
MenACWY-TT vaccine), or concomitantly with (Group A; test
group), a TT-containing DTaP-IPV-HB-PRP-T vaccine. As adminis-
tration of MenACWY-TT one month after a TT-containing vaccine
was not recommended, and as Nimenrix did not have any co-
administration labelling claim with Prevenar 13, MenC-TT vaccine
was administered instead of MenACWY-TT vaccine to subjects in
Group B (control group for the DTaP-IPV-HB-PRP-T vaccine) at
approximately 13 months of age to ensure protection against
MenC serogroup.
2.3. Study design
This phase III, open-label, randomised, multicentre study (clin-
icaltrial.gov: NCT01839175; EudraCT: 2012-005547-24) was con-
ducted at 11 vaccine research clinics in Finland.
The randomisation was stratified by groups from the primary
series (i.e., Group 1: DTaP-IPV-HB-PRP-T vaccine co-administered
with MenC vaccine; Group 2: DTaP-IPV-HB-PRP-T vaccine without
MenC-TT vaccine). Participants enrolled in the booster phase were
randomly assigned in a 1:1:1 ratio to one of three vaccination
groups irrespective of their primary series enrolment group. In
Group A, participants received a dose of DTaP-IPV-HB-PRP-T vac-
cine with a dose of MenACWY-TT vaccine at approximately
12 months of age, and 28–42 days later they received a dose of
Prevenar 13 (i.e., at approximately 13 months of age). In Group B,
participants received a dose of DTaP-IPV-HB-PRP-T vaccine at
approximately 12 months of age, and doses of MenC-TT vaccine
and Prevenar 13 at approximately 13 months of age. In Group C,
participants received a dose of MenACWY-TT vaccine at approxi-
mately 12 months of age, and a dose of the DTaP-IPV-HB-PRP-T
vaccine plus a dose of Prevenar 13 at approximately 13 months
of age. All participants were offered an optional dose of M-M-
RvaxPro at approximately 13 months of age.
The trial was conducted in accordance with applicable local and
national requirements and guidelines, the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use, Good Clinical Practice standards, the Ethical Principles
for Medical Research Involving Human Subjects of the World Med-
ical Association, and the Declaration of Helsinki. The parent(s) or
legal guardian(s) of the participating children provided written
informed consent prior to inclusion in the booster part.
2.4. Immunogenicity measurements
Serology tests for DTaP-IPV-HB-PRP-T vaccine antigens and
MenC/MenACWY-TT vaccine antigens were performed by two dif-
ferent laboratories: Public Health England’s Vaccine Evaluation
Unit (Manchester, UK) for MenC, MenA, MenW and MenY; and
the Global Clinical Immunology platform (Sanofi Pasteur Inc.,
T. Vesikari et al. / Vaccine 36 (2018) 8019–8027 8021Swiftwater, PA, USA) for pertussis, hepatitis B, Hib, diphtheria tox-
oid, tetanus toxoid, and inactivated poliovirus antigens. Laboratory
staff were blinded to the group to which participants were
randomised.
The serological analyses were performed as described in the pri-
mary series article [7]. The immunogenicity assessments used for
the DTaP-IPV-HB-PRP-T vaccine were consistent with those used
during the clinical development plan with regards to the assays
used, the endpoints analysed, and the timing of the serology
assessment. The meningococcal serogroup A, W and Y antibodies
were tested by the modified serum bactericidal antibody (SBA)
assay with baby rabbit complement, as previously described by
Maslanka et al. [13].
Blood samples of approximately 5 mL each were collected
before and one month after the booster vaccination (at 13 months
of age). The antibody correlates of protection for each vaccine anti-
gen were as described for the primary series, with the addition of
meningococcal serogroup A, W and Y endpoints (SBA titre  8).
2.5. Safety assessments
Safety and tolerability for related serious adverse events (SAEs),
deaths and adverse events of special interest (AESIs) were moni-
tored between the end of the primary series study and booster vac-
cination day (at approximately 12 months of age). Within 30 min
of booster vaccination, investigators monitored participants for
unsolicited (spontaneously reported) systemic adverse events
(AEs) or SAEs.
A diary card was provided at approximately 12 months of age
(booster vaccination day, day 0) that participants’ parents or legal
guardians used on days 0–7 to record solicited injection-site
adverse reactions (injection-site erythema, injection-site pain,
injection-site swelling) and solicited systemic adverse reactions
(pyrexia, vomiting, crying, somnolence, anorexia and irritability).
Unsolicited injection-site reactions and systemic AEs were
recorded on days 0–30. Parents or legal guardians recorded the
start, end and intensity of any unsolicited events; the investigator
assessed the relationship of these events to the vaccination. Seri-
ous AEs, including deaths, and AESIs were recorded from approxi-
mately 12 to 13 months of age. For children randomised to Group
C, a telephone contact was made at approximately 14 months of
age to collect any relevant safety information.
2.6. Statistical methods
2.6.1. Sample size
Sample size for the primary series was determined as previ-
ously reported [7]. The maximum number of participants in the
primary series was expected to be 350; all children who received
three doses of the DTaP-IPV-HB-PRP-T vaccine were to be invited
to participate in the booster study. We estimated that a participa-
tion rate in the booster phase of 70–85% would result in 245–298
participants being evaluable for the primary analysis. With a sam-
ple size of 80 evaluable participants per group, the half-width of
the two-sided 95% confidence interval (CI) should not exceed 10%
for observed response rates above 80%.
2.6.2. Analyses
Descriptive statistics were used for the immunogenicity and
safety analyses. The randomised set was defined as all randomised
subjects in the booster part of the study. The persistence analysis
was performed on the persistence analysis set (all children ran-
domised and who provided a blood sample on booster vaccination
day).
The post-booster immunogenicity primary analyses were per-
formed on the per-protocol set (PPS; randomised participantsexcluding those with protocol deviation(s) that could interfere
with the immunogenicity evaluation).
The full analysis sets (all randomised participants who received
at least one dose of the study vaccines and who had any post-
vaccination immunogenicity data) were used for supportive
analyses.
Safety analyses were described for all participants with safety
follow-up data who received at least one dose of study vaccine(s)
(safety analysis set).
Statistical analyses were performed using SAS software ver-
sion 9.1.3 (SAS Institute Inc., Cary, NC, USA).3. Results
3.1. Demographic and other baseline characteristics
At 12 months of age, 312 toddlers (mean age 376.5 days; range:
366–415 days) previously primed at two, three and four months of
age with DTaP-IPV-HB-PRP-T vaccine with or without MenC-TT
vaccine were randomised as follows:
 104 toddlers received DTaP-IPV-HB-PRP-T co-administered
with MenACWY-TT (Group A)
 105 toddlers received DTaP-IPV-HB-PRP-T alone (Group B)
 103 toddlers received MenACWY-TT alone (Group C).
Demographic and baseline characteristics were similar across
the three groups in terms of age, ethnic origin and temperature
in the overall randomised set (Table 1). The participant disposition
is summarised in Fig. 1. In the PPS, demographic and baseline char-
acteristics were similar across the groups.
3.2. Pre-booster antibody persistence to DTaP-IPV-HB-PRP-T vaccine
antigens (persistence analysis set)
Following the three-dose primary vaccination series at two,
three and four months of age, no notable differences were observed
at 12 months of age between Group 1 (DTaP-IPV-HB-PRP-T vaccine
co-administered with the MenC-TT vaccine) and Group 2 (DTaP-
IPV-HB-PRP-T vaccine without MenC-TT vaccine) in terms of anti-
body levels to the different DTaP-IPV-HB-PRP-T vaccine antigens,
with the exception of the proportion of participants with an anti-
T concentration  0.10 IU/mL, which was higher in Group 1 versus
Group 2 (100%, 95% CI: 97.6; 100.0, and 92.0%, 95% CI: 86.4; 95.8,
respectively) (Table 2).
At 12 months of age, there were no notable differences in geo-
metric mean concentrations (GMCs) or titres (GMTs) between
Group 1 and Group 2 for any DTaP-IPV-HB-PRP-T vaccine antigen
with the exception of anti-T GMC, which was significantly higher
in Group 1 versus Group 2 (0.61, 95%CI: 0.55; 0.68, and 0.34, 95%
CI: 0.29; 0.39, respectively) (Supplementary Data 2).
3.3. Post-booster antibody response to DTaP-IPV-HB-PRP-T vaccine
antigens (PPS)
One month after the booster dose, no notable differences were
observed between Group A (DTaP-IPV-HB-PRP-T with MenACWY-
TT) and Group B (DTaP-IPV-HB-PRP-T alone) in terms of seropro-
tection rates (Group A: 97.7–100%; Group B: 98.9–100%) for any
DTaP-IPV-HB-PRP-T vaccine antigen (PPS) (Table 3).
The proportions of participants with anti-D concentra-
tion  1.0 IU/mL and anti-T concentration  1.0 IU/mL were also
high and comparable in both groups. For pertussis antigens, the
proportion of participants with vaccine response (from
pre-vaccination [pre-dose 1] to post-booster) for pertussis toxoid
Table 1
Demography and other baseline characteristics (randomised set).
Group A
DTaP-IPV-HB-PRP-T with MenACWY
(N = 104)
Group B
DTaP-IPV-HB-PRP-T alone
(N = 105)
Group C
MenACWY-TT alone
(N = 103)
Total
(N = 312)
Age (days) at vaccination
n 104 105 103 312
Mean (SD) 375.8 (8.8) 376.8 (9.4) 376.8 (9.2) 376.5 (9.1)
Median 373.0 374.0 374.0 373.0
Min; max 366; 406 366; 415 366; 410 366; 415
Sex
n 104 105 103 312
Female, n (%) 49 (47.1)* 54 (51.4)* 46 (44.7)* 149 (47.8)*
Male, n (%) 55 (52.9)* 51 (48.6)* 57 (55.3)* 163 (52.2)*
Ethnic origin
n 104 105 103 312
Asian, n (%) 0 1 (1.0)* 0 1 (0.3)*
Black, n (%) 1 (1.0)* 0 0 1 (0.3)*
Caucasian, n (%) 96 (92.3)* 100 (95.2)* 95 (92.2)* 291 (93.3)*
Other, n (%) 7 (6.7)* 4 (3.8)* 8 (7.8) 19 (6.1)*
Temperature (C)
n 104 105 103 312
Mean (SD) 36.6 (0.6) 36.6 (0.6) 36.6 (0.6) 36.6 (0.6)
Median 36.6 36.6 36.6 36.6
Min; max 35.3; 37.9 35.4; 37.8 35.1; 37.7 35.1; 37.9
Disposition of subjects according to groups in the primary seriesy
Hexavalent co-administered with MenC
(Group 1), n (%)
53 (51.0)* 52 (49.5)* 51 (49.5)* 156 (50.0)*
Hexavalent without MenC (Group 2), n (%) 51 (49.0)* 53 (50.5)* 52 (50.5)* 156 (50.0)*
Abbreviations: aP, acellular pertussis; D, diphtheria; HB, hepatitis B; IPV, inactivated poliovirus; MenACWY, meningococcal serogroups A, C, W and Y; PRP, Haemophilus
influenzae type-b capsular polyribosyl-ribitol-phosphate; SD, standard deviation; T, tetanus; TT, tetanus toxoid.
* Percentages are based on the number of randomised subjects.
y Vaccines actually received during the primary series part.
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tively, in both Group A and Group B. The proportion of participants
with a four-fold-rise from pre-vaccination (pre-dose 1) to post-
booster for pertussis toxoid and filamentous haemagglutinin were
respectively 83.5% and 96.5% in Group A, and 88.4% and 92.1% in
Group B.
There were no notable differences in GMCs/GMTs for any DTaP-
IPV-HB-PRP-T vaccine antigen between Group A and Group B
except for anti-IPV3 GMT and anti-PRP GMC, which tended to be
higher in Group B but deemed not to be clinically significant
(Table 3). Comparable results for seroprotection rates/response
rates and GMCs/GMTs were observed in the full analysis set
DTaP-IPV-HB-PRP-T.
3.3.1. Antibody response to MenACWY-TT vaccine antigens (PPS)
In the PPS, one month after vaccination no notable differences
were observed between Group A (DTaP-IPV-HB-PRP-T with
MenACWY-TT) and Group C (MenACWY-TT alone) in terms of sero-
protection rates for any meningococcal serogroup. The proportion
of participants with an antibody titre  8 (1/dil) was high in both
groups, ranging from 98.9 to 100% in Group A, and 95.7 to 100%
in Group C (Table 4).
There were no notable differences in GMTs between Group A
and Group C for any meningococcal antigen except for MenA SBA
GMT, which tended to be higher in Group C (Table 4). For both
Group A and Group C, the subgroup of participants who had previ-
ously received the MenC vaccine during the primary series part
(Group 1) displayed higher anti-MenC GMTs versus the subgroup
of participants who did not (Group 2) (data not shown).
3.4. Safety
The safety profile of the DTaP-IPV-HB-PRP-T vaccine was gener-
ally comparable whether co-administered with MenACWY-TT vac-
cine or not (Table 5). Overall, most of the participants reported AEsoccurring within 30 days after vaccination: 94.2% in Group A
(DTaP-IPV-HB-PRP-T with MenACWY-TT), 92.4% in Group B
(DTaP-IPV-HB-PRP-T alone), and 87.4% in Group C (MenACWY-TT
alone). Two participants (0.6% of all participants), one in Group A
(1.0%) and one in Group B (1.0%), experienced an immediate unso-
licited AE after the booster – grade 1 urticaria and grade 2 diar-
rhoea, respectively – both considered by the investigator to be
related to the study vaccines.
Solicited injection site reactions within seven days after DTaP-
IPV-HB-PRP-T vaccination were reported by 66.0% of subjects in
Group A, and 60.0% of subjects in Group B.
Solicited injection site reactions within seven days after
MenACW-TT vaccination were reported by 47.6% of subjects in
Group A, and 32.0% of subjects in Group C, and injection site pain
was reported more frequently in Group A (46.6% versus 17.5%).
Grade 3 intensity reactions were observed in 11% in Group A and
1% in Group C.
Nearly all solicited injection site reactions occurred between
day 0 and day 3 following vaccination, and lasted no more than
three days (Table 5). The details of the intensity scales used for
safety parameters are shown in Supplementary Data 3.
The frequency of solicited systemic reactions was higher in
Group A versus Group C for crying, irritability, pyrexia and somno-
lence (respectively: 50.5% versus 30.1%; 76.7% versus 48.5%; 30.1%
versus 10.7%; and 52.4% versus 32.0%). No notable differences were
observed between Group A and Group C in frequencies of reactions
of Grade 3 intensity. Pyrexia of grade 3 intensity (>39.5 C) was
reported by four participants: two who received DTaP-IPV-HB-
PRP-T and MenACWY-TT vaccine concomitantly; one who received
DTaP-IPV-HB-PRP-T vaccine alone; and one who received
MenACWY-TT vaccine alone.
One AESI was reported during the booster phase, a serious
febrile convulsion related to pneumonia caused by respiratory
syncytial viral infection reported 24 days after administration of
MenACWY-TT vaccine alone. The number of SAEs reported was
Fig. 1. Disposition of patients through the study. aParticipants who received three doses of the DTaP-IPV-HB-PRP-T vaccine during the primary series part. bOne participant
randomised to Group A (DTaP-IPV-HB-PRP-T vaccine co-administered with MenACWY-TT vaccine) had received the DTaP-IPV-HB-PRP-T vaccine prior to randomisation (and
received the MenC vaccine at approximately 13 months of age). cOne participant was lost to follow-up after vaccination at approximately 12 months of age, with no safety
data available.
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the investigator. No AE leading to study discontinuation during the
booster phase of the study were reported during the course of that
part of the study.4. Discussion
The results demonstrate that, one month after vaccination with
a booster dose, the immune responses elicited by the DTaP-IPV-
HB-PRP-T vaccine and the meningococcal serogroup ACWY
Table 3
Summary of post-booster antibody levels (A) and geometric means of antibody concentrations or titres (B) to DTaP-IPV-HB-PRP-T vaccine antigens (PPS).
Group A
Hexavalent co-administered with MenACWY (N = 87)
Group B
Hexavalent alone (N = 91)
A. Post-booster antibody levels
Component Endpoint M* n (%) 95% CI M* n (%) 95% CI
Anti-D 0.10 IU/mL 87 87 (100.0) 95.8; 100.0 91 91 (100.0) 96.0; 100.0
1.0 IU/mL 87 78 (89.7) 81.3; 95.2 91 88 (96.7) 90.7; 99.3
Anti-T 0.10 IU/mL 87 87 (100.0) 95.8; 100.0 91 91 (100.0) 96.0; 100.0
1.0 IU/mL 87 84 (96.6) 90.3; 99.3 91 88 (96.7) 90.7; 99.3
Anti-IPV1 8 1/dil 87 86 (98.9) 93.8; 100.0 91 90 (98.9) 94.0; 100.0
Anti-IPV2 8 1/dil 87 87 (100.0) 95.8; 100.0 91 91 (100.0) 96.0; 100.0
Anti-IPV3 8 1/dil 87 87 (100.0) 95.8; 100.0 90 90 (100.0) 96.0; 100.0
Anti-HBs 10 mIU/mL 87 86 (98.9) 93.8; 100.0 91 90 (98.9) 94.0; 100.0
100 mIU/mL 85 85 (97.7) 91.9; 99.7 91 87 (95.6) 89.1; 98.8
Anti-PRP 0.15 mg/mL 87 87 (100.0) 95.8; 100.0 91 91 (100.0) 96.0; 100.0
1.0 mg/mL 87 85 (97.7) 91.9; 99.7 91 91 (100.0) 96.0; 100.0
Anti-PT Vaccine responsey 85 84 (98.8) 93.6; 100.0 86 85 (98.8) 93.7; 100.0
4-fold increase 85 71 (83.5) 73.9; 90.7 86 76 (88.4) 79.7; 94.3
Anti-FHA Vaccine responsey 85 85 (100.0) 95.8; 100.0 89 89 (100.0) 95.9; 100.0
4-fold increase 85 82 (96.5) 90.0; 99.3 89 82 (92.1) 84.5; 96.8
B. Post-booster GMTs/GMCs
Component M Geometric mean (GMC/GMT)§ 95% CI M Geometric mean (GMC/GMT)§ 95% CI
Anti-D (IU/mL) 87 3.07 2.49; 3.79 91 3.24 2.69; 3.91
Anti-T (IU/mL) 87 6.89 5.78; 8.21 91 6.25 5.30; 7.37
Anti-IPV1 (1/dil) 87 2174.05 1606.18; 2942.70 91 2040.21 1522.96; 2733.14
Anti-IPV2 (1/dil) 87 1678.14 1203.60; 2339.77 91 1738.58 1242.59; 2432.56
Anti-IPV3 (1/dil) 87 3086.91 2278.10; 4182.89 90 4127.67 3175.40; 5365.53
Anti-HBs (mIU/mL) 87 2230.68 1597.48; 3114.87 91 2233.15 1597.30; 3122.13
Anti-PRP (mg/mL) 87 22.70 17.20; 29.96 91 27.82 21.89; 35.35
Anti-PT (EU/mL) 87 111.78 97.90; 127.63 91 114.72 102.68; 128.16
Anti-FHA (EU/mL) 87 174.98 153.98; 198.86 91 184.57 162.43; 209.72
Abbreviations: CI, confidence interval; D, diphtheria; FHA, filamentous haemagglutinin; GMC, geometric mean concentration; GMT, geometric mean titre; HBs, hepatitis B;
IPV, inactivated poliovirus; LLOQ, lower limit of quantitation; MenACWY, meningococcal serogroups A, C, W and Y; PRP, Haemophilus influenzae type b capsular polyribosyl-
ribitol-phosphate; PPS, per-protocol set; PT, pertussis toxoid; T, tetanus.
* M: number of subjects with available data.
y Pertussis vaccine response was defined as:
 if pre-vaccination (pre-dose 1) antibody concentration < 4  LLOQ, then post-booster antibody concentration  4  LLOQ
 if pre-vaccination (pre-dose 1) antibody concentration  4  LLOQ, then post-booster antibody concentration > pre-vaccination antibody concentration.
 Increase from pre-vaccination (pre-dose 1) to post-booster.
§ GMCs for anti-D, anti-T, anti-HBs, anti-PRP, anti-PT, and anti-FHA; GMTs for anti-IPV1, anti-IPV2 and anti-IPV3.
Table 2
Summary of antibody levels at 12 months of age for all DTaP-IPV-HB-PRP-T antigens following the three-dose primary vaccination (pre-booster) (persistence analysis set).
Group 1 (primary series part)
DTaP-IPV-HB-PRP-T co-administered with MenC
(N = 152)
Group 2 (primary series part)
DTaP-IPV-HB-PRP-T without MenC (N = 151)
Component Endpoint M* n (%) 95% CI M* n (%) 95% CI
Anti-D 0.01 IU/mL 151 148 (98.0) 94.3; 99.6 150 149 (99.3) 96.3; 100.0
0.10 IU/mL 151 62 (41.1) 33.1; 49.3 150 71 (47.3) 39.1; 55.6
Anti-T 0.01 IU/mL 151 151 (100.0) 97.6; 100.0 150 150 (100.0) 97.6; 100.0
0.10 IU/mL 151 151 (100.0) 97.6; 100.0 150 138 (92.0) 86.4; 95.8
Anti-IPV1 8 1/dil 151 122 (80.8) 73.6; 86.7 150 127 (84.7) 77.9; 90.0
Anti-IPV2 8 1/dil 151 98 (64.9) 56.7; 72.5 150 114 (76.0) 68.4; 82.6
Anti-IPV3 8 1/dil 150 123 (82.0) 74.9; 87.8 148 131 (88.5) 82.2; 93.2
Anti-HB 10 mIU/mL 152 137 (90.1) 84.2; 94.4 151 138 (91.4) 85.7; 95.3
100 mIU/mL 152 72 (47.4) 39.2; 55.6 151 77 (51.0) 42.7; 59.2
Anti-PRP 0.15 mg/mL 151 131 (86.8) 80.3; 91.7 150 116 (77.3) 69.8; 83.8
1.0 mg/mL 151 70 (46.4) 38.2; 54.6 150 71 (47.3) 39.1; 55.6
Anti-PT LLOQy 151 151 (100.0) 97.6; 100.0 148 147 (99.3) 96.3; 100.0
2  LLOQy 151 150 (99.3) 96.4; 100.0 148 147 (99.3) 96.3; 100.0
Anti-FHA LLOQy 151 151 (100.0) 97.6; 100.0 149 149 (100.0) 97.6; 100.0
2  LLOQy 151 151 (100.0) 97.6; 100.0 149 149 (100.0) 97.6; 100.0
Abbreviations: aP, acellular pertussis; CI, confidence interval; D, diphtheria; FHA, filamentous haemagglutinin; HB, hepatitis B; IPV, inactivated poliovirus; LLOQ, lower limit
of quantitation; MenC, meningococcal serogroup C; PRP, Haemophilus influenzae type b capsular polyribosyl-ribitol-phosphate; PT, pertussis toxoid; T, tetanus.
* M: number of subjects with available data.
y LLOQ = 2 EU/mL for PT and FHA.
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Table 4
Summary of post-vaccination antibody levels (A) and geometric means of antibody titres (B) for MenACWY-TT vaccine antigens (PPS).
Group A
Hexavalent co-administered with MenACWY (N = 87)
Group C
MenACWY alone (N = 94)
A. Post-vaccination antibody levels
Component Endpoint (1/dil) M* n (%) 95% CI M* n (%) 95% CI
Anti-MenA 8 87 87 (100.0) 95.8; 100.0 94 94 (100.0) 96.2; 100.0
Anti-MenC 8 All subjects 87 86 (98.9) 93.8; 100.0 94 90 (95.7) 89.5; 98.8
Subjects who received the MenC vaccine in
primary series party
43 43 (100.0) 91.8; 100.0 47 46 (97.9) 88.7; 99.9
Subjects who did not receive any MenC
vaccine in primary series part
44 43 (97.7) 88.0; 99.9 47 44 (93.6) 82.5; 98.7
128 All subjects 87 85 (97.7) 91.9; 99.7 94 85 (90.4) 82.6; 95.5
Subjects who received the MenC vaccine in
primary series party
43 43 (100.0) 91.8; 100.0 47 46 (97.9) 88.7; 99.9
Subjects who did not receive any MenC
vaccine in primary series part
44 42 (95.5) 84.5; 99.4 47 39 (83.0) 69.2; 92.4
Anti-MenW 8 87 87 (100.0) 95.8; 100.0 94 93 (98.9) 94.2; 100.0
Anti-MenY 8 87 87 (100.0) 95.8; 100.0 94 94 (100.0) 96.2; 100.0
B. Post-booster GMTs
Component M Geometric mean
(GMT)
95% CI M Geometric mean
(GMT)
95% CI
Anti-MenA 87 4096.00 3335.98;
5029.17
94 5302.07 4249.49;
6615.38
Anti-MenC
All subjects 87 693.03 524.15;
916.33
94 620.20 425.53;
903.94
Subjects who received the MenC vaccine in primary series party 43 1262.73 901.11;
1769.46
47 1617.53 1083.22;
2415.39
Subjects who did not receive any MenC vaccine in primary series part 44 385.59 264.11;
562.93
47 237.80 141.85;
398.66
Anti-MenW 87 2148.28 1650.66;
2795.91
94 2555.07 1930.58;
3381.58
Anti-MenY 87 1952.40 1538.58;
2477.53
94 2003.19 1592.49;
2519.81
Abbreviations: CI, confidence interval; GMT, geometric mean titre; MenACWY, meningococcal serogroups A, C, W and Y; PPS, per-protocol set; TT, tetanus toxoid.
* M: number of subjects with available data.
y Subjects from Group 1 in primary series: hexavalent vaccine co-administered with MenC vaccine.
 Subjects from Group 2 in primary series: hexavalent vaccine without MenC vaccine.
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when administration is staggered at different time points, are high
for any vaccine antigen.
Overall, concomitant administration of the DTaP-IPV-HB-PRP-T
and MenACWY-TT vaccines did not affect the immune response to
either vaccine: the similar response rates and antibody GMCs/
GMTs between the groups are supportive of concomitant adminis-
tration of the two vaccines when given at 12 months of age in
healthy toddlers. The seroprotection rates/response rates and the
antibody GMCs/GMTs reported for the different antigens contained
in the DTaP-IPV-HB-PRP-T vaccine in the present study were con-
sistent with those previously reported and/or summarised for the
vaccine used in booster vaccination, irrespective of the primary
immunisation schedule for DTaP-IPV-HB-PRP-T (including a two-,
three-, four-month schedule) [7,8,14–17]. Similarly, the seropro-
tection rates/response rates and the antibody GMTs reported for
the meningococcal serogroup A, C, W and Y conjugate vaccine
antigens were consistent with those previously reported with the
MenACWY-TT vaccine for the toddler population [9], and
when co-administered with the DTaP-IPV-HB-PRP-T vaccine
Infanrix-hexa [18].
The immunogenicity assessment used for the MenACWY-TT
vaccine (rabbit SBA) was consistent with that generally used for
this type of vaccine (including Nimenrix) [9,18–20]. Furthermore,
the use of MenC vaccine in the primary series schedule did not pre-clude the use of MenACWY-TT for co-administration with a DTaP-
IPV-HB-Hib booster dose post-booster, and response rates/
antibody GMTs were high for all MenACWY antigens whether
MenC-TT vaccine was used in the primary series schedule or not.
Prior receipt of MenC-TT vaccine in the current study led to a
higher GMT for MenC antigen, as previously documented [21].
Antibody persistence at 12 months of age against the DTaP-IPV-
HB-PRP-T vaccine antigens was similar between primary series
groups except for higher anti-T antibody level in subjects who
had received both TT-containing vaccines (DTaP-IPV-HB-PRP-T
and MenC). At 12 months of age, a high proportion of subjects
retained antibody levels associated with short-term protection
that are consistent with those previously observed after a 2, 3
and 4 months priming [17] and equal to or higher than those
observed in a similar population receiving two-dose priming at 3
and 5 months of age [22]. This finding supports the administration
of a booster dose, as confirmed by the subsequent robust post-
booster response in all booster groups.
The co-administration of the hexavalent DTaP-IPV-HB-PRP-T
vaccine and of the MenACWY-TT conjugate vaccine resulted in
higher reactogenicity for many systemic signs. The frequency
of injection site adverse reactions reported in this present study
for the MenACWY-TT vaccine was consistent with clinical trials
data reported in the Nimenrix summary of product characteris-
tics [9].
Table 5
Safety overview from approximately 12 to 13 months of age (safety analysis set).
Group A DTaP-IPV-HB-PRP-T
co-administered with
MenACWY (N = 103)
Group B DTaP-IPV-HB-PRP-T
alone (N = 105)
Group C MenACWY-TT alone
(N = 103)
Period/participants with at least one of the following: n (%) 95% CI
(participants)*
n (%) 95% CI
(participants)*
n (%) 95% CI
(participants)*
AE within 30 days after any injection at approximately 12 months
of age
97
(94.2)
87.8; 97.8 97
(92.4)
85.5; 96.7 90
(87.4)
79.4; 93.1
Immediate unsolicited AE 1 (1.0) <0.1; 5.3 1 (1.0) <0.1; 5.2 0 –
Solicited reactions within 7 days after booster vaccination 96
(93.2)
86.5; 97.2 96
(91.4)
84.4; 96.0 80
(77.7)
68.4; 85.3
Grade 3 solicited reaction 14
(13.6)
7.6; 21.8 11
(10.5)
5.3; 18.0 5 (4.9) 1.6; 11.0
Solicited injection site reaction 71
(68.9)
59.1; 77.7 63
(60.0)
50.0; 69.4 33
(32.0)
23.2; 42.0
Grade 3 ISR 11
(10.7)
5.5; 18.3 5 (4.8) 1.6; 10.8 1 (1.0) <0.1; 5.3
After Hexavalent vaccine 68
(66.0)
56.0; 75.1 63
(60.0)
50.0; 69.4 NA –
Grade 3 ISR 10 (9.7) 4.8; 17.1 5 (4.8) 1.6; 10.8 NA –
After MenACWY vaccine 49
(47.6)
37.6; 57.6 NA – 33
(32.0)
23.2; 42.0
Grade 3 ISR 1 (1.0) <0.1; 5.3 NA – 1 (1.0) <0.1; 5.3
Solicited systemic reaction 91
(88.3)
80.5; 93.8 90
(85.7)
77.5; 91.8 75
(72.8)
63.2; 81.1
Grade 3 solicited systemic reaction 5 (4.9) 1.6; 11.0 6 (5.7) 2.1; 12.0 4 (3.9) 1.1; 9.6
Unsolicited non-serious systemic AE 53
(51.5)
41.4; 61.4 50
(47.6)
37.8; 57.6 60
(58.3)
48.1; 67.9
Unsolicited non-serious systemic AR 5 (4.9) 1.6; 11.0 4 (3.8) 1.0; 9.5 1 (1.0) <0.1; 5.3
AE leading to study discontinuation 0 – 0 – 0 –
SAE 1 (1.0) <0.1; 5.3 0 – 1 (1.0) <0.1; 5.3
SAR 0 – 0 – 0 –
Death 0 – 0 – 0 –
AESI/SAE from approximately 12–13 months of age 97
(94.2)
87.8; 97.8 97
(92.4)
85.5; 96.7 90
(87.4)
79.4; 93.1
AESI 0 – 0 – 1 (1.0) <0.1; 5.3
SAEs 1 (1.0) <0.1; 5.3 1 (1.0)y <0.1; 5.2 1 (1.0) <0.1; 5.3
Related to Hexyon 0 – 0 – 0 –
Death 0 – 0 – 0 –
Abbreviations: AE, adverse event; AESI, adverse event of special interest; aP, acellular pertussis; AR, adverse reaction; CI, confidence interval; D, diphtheria; HB, hepatitis B;
IPV, inactivated poliovirus; ISR, injection site reactions; MenACWY, meningococcal serogroups A, C, W and Y; NA, not applicable; PRP, Haemophilus influenzae type b capsular
polyribosyl-ribitol-phosphate; SAE, serious adverse event; SAR, serious adverse reaction; T, tetanus; TT, tetanus toxoid.
* Two-sided 95% CIs of the percentage of participants presenting the specified event at least once were calculated using the exact binomial method.
y This event occurred 64 days after vaccination at approximately 12 months of age (visit 5); consequently, the visit at 13 months of age was delayed and performed 85 days
after visit 5.
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Co-administration of DTaP-IPV-HB-PRP-T vaccine with
MenACWY-TT vaccine did not affect the immune response to
either vaccine. Prior receipt of MenC-TT conjugate vaccine during
infancy did not preclude the use of a MenACWY-TT vaccine for
booster vaccination and resulted in higher responses to MenC after
booster.
The immunogenicity and safety findings of this study support
the concomitant administration of the DTaP-IPV-HB-PRP-T vaccine
with a MenACWY-TT conjugate vaccine when given from
12 months of age, but a higher systemic reaction rate after con-
comitant vaccination should be noted.
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